FDA Brief

Warning letters Food

FDA warning letter to

LIV Health LLC dba INFINIWELL and DEAL Media L.L.C. dba HARMONIA

High riskIssued Nov 23, 2021Posted Nov 30, 2021Office of Human and Animal Foods Operations‐East V

FDA warned LIV Health/INFINIWELL and DEAL Media/HARMONIA that seven products were sold as unapproved new drugs via disease-treatment claims.

What happened

FDA reviewed the companies’ websites in August–September 2021 and found they took orders for seven products and made claims that the products treat thyroid disease, anxiety, insomnia, high cholesterol, and Alzheimer’s disease. FDA said these claims make the products drugs intended to cure, mitigate, treat, or prevent disease. Because the products are not generally recognized as safe and effective for those uses, FDA called them unapproved new drugs and said they are misbranded because they lack adequate directions for use.

What FDA found

  1. The products are unapproved new drugs because they are not generally recognized as safe and effective for their claimed uses.

    section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  2. The website claims make the products drugs because they are intended to cure, mitigate, treat, or prevent disease.

    section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  3. The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended uses.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5

What FDA wants

FDA asks the companies to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, with an explanation of each step and supporting documents. If corrective action cannot be completed in that time, they must state the reason and the planned completion time; if they disagree, they must include their reasoning and supporting information.

Who should pay attention

  • supplement brands and online sellers making disease-treatment claims
  • retailers or marketplaces listing thyroid, sleep, anxiety, or cognitive-support products
  • compliance teams reviewing website claims and product labels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk